Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760621 | 0.72 | PTGDR2 (0.35) | PTGDR2 | |
| SCHEMBL5760617 | 0.72 | PTGDR2 (0.35) | PTGDR2 | |
| SCHEMBL29138593 | 0.69 | ESR2 (0.37) | — | |
| SCHEMBL5760376 | 0.69 | PTGDR2 (0.37) | PTGDR2 | |
| SCHEMBL5760375 | 0.69 | PTGDR2 (0.37) | PTGDR2 | |
| SCHEMBL17101636 | 0.69 | MAPK1 (0.62) | PTGDR2 | |
| SCHEMBL4968048 | 0.67 | JAK3 (0.36) | — | |
| SCHEMBL20371552 | 0.67 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL628725 | 0.67 | ESR2 (0.43) | — | |
| SCHEMBL4272274 | 0.65 | DRD2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026093-B | Crystalline forms | 爱杜西亚药品有限公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-3350179-B1 | CRYSTALLINE FORMS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-01-13 | — | — | EP | disclosed |
| US-10351560-B2 | Crystalline forms | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-07-16 | — | — | US | disclosed |
| US-10301309-B2 | Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20190047996-A1 | CRYSTALLINE FORMS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2019-02-14 | — | — | US | disclosed |
| EP-3350179-A1 | CRYSTALLINE FORMS | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-25 | — | — | EP | disclosed |
| EP-3119779-B1 | AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-11 | — | — | EP | disclosed |
| US-20180105520-A1 | AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | disclosed |
| US-9879006-B2 | Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators | IDORSIA PHARMACEUTICALS LTD | 2018-01-30 | — | — | US | disclosed |
| WO-2017046125-A1 | CRYSTALLINE FORMS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-23 | — | — | WO | disclosed |
| US-20170022196-A1 | AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-01-26 | — | — | US | disclosed |
| EP-3119779-A1 | AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd (CH) | 2017-01-25 | — | — | EP | disclosed |
| CN-106103435-A | Azaindole acetogenin and they are as the purposes of prostaglandin D 2 receptor conditioning agent | 埃科特莱茵药品有限公司 | 2016-11-09 | — | — | CN | disclosed |
| WO-2015140684-A1 | AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022196-A1 | AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885 |
| US-10301309-B2 | Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885 |
| US-20180105520-A1 | AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885 |
| US-20190047996-A1 | CRYSTALLINE FORMS | HRH2, HRH1, HRH3 | PTGDR2 200/4885 |
| US-10351560-B2 | Crystalline forms | HRH2, HRH1, HRH3 | PTGDR2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.